These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 33726710)
1. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma. Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710 [TBL] [Abstract][Full Text] [Related]
2. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial. Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434 [TBL] [Abstract][Full Text] [Related]
3. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas. Moon HH; Kim HS; Park JE; Kim YH; Kim JH BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252 [TBL] [Abstract][Full Text] [Related]
4. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. Gainer JL; Sheehan JP; Larner JM; Jones DR J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177 [TBL] [Abstract][Full Text] [Related]
5. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362 [TBL] [Abstract][Full Text] [Related]
7. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912 [TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487 [TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy. Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K Oncology; 2019; 97(5):255-263. PubMed ID: 31288238 [TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression as an adverse event of glioblastoma therapy. Balaña C; Capellades J; Pineda E; Estival A; Puig J; Domenech S; Verger E; Pujol T; Martinez-García M; Oleaga L; Velarde J; Mesia C; Fuentes R; Marruecos J; Del Barco S; Villà S; Carrato C; Gallego O; Gil-Gil M; Craven-Bartle J; Alameda F; Cancer Med; 2017 Dec; 6(12):2858-2866. PubMed ID: 29105360 [TBL] [Abstract][Full Text] [Related]
11. Defining pseudoprogression in glioblastoma multiforme. Van Mieghem E; Wozniak A; Geussens Y; Menten J; De Vleeschouwer S; Van Calenbergh F; Sciot R; Van Gool S; Bechter OE; Demaerel P; Wilms G; Clement PM Eur J Neurol; 2013 Oct; 20(10):1335-41. PubMed ID: 23679051 [TBL] [Abstract][Full Text] [Related]
12. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000 [TBL] [Abstract][Full Text] [Related]
13. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Sanghera P; Perry J; Sahgal A; Symons S; Aviv R; Morrison M; Lam K; Davey P; Tsao MN Can J Neurol Sci; 2010 Jan; 37(1):36-42. PubMed ID: 20169771 [TBL] [Abstract][Full Text] [Related]
15. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience. Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468 [TBL] [Abstract][Full Text] [Related]
17. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780 [TBL] [Abstract][Full Text] [Related]
18. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325 [TBL] [Abstract][Full Text] [Related]
19. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. Brahm CG; den Hollander MW; Enting RH; de Groot JC; Solouki AM; den Dunnen WFA; Heesters MAAM; Wagemakers M; Verheul HMW; de Vries EGE; Pruim J; Walenkamp AME Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2404-2412. PubMed ID: 30032322 [TBL] [Abstract][Full Text] [Related]
20. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. Lopes M; Carvalho B; Vaz R; Linhares P J Neurooncol; 2018 Jan; 136(1):173-180. PubMed ID: 29076002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]